NYSE:BLCO Bausch + Lomb - BLCO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bausch + Lomb Co. Please log in to your account or sign up in order to add this asset to your watchlist. $17.29 -0.23 (-1.31%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$17.22▼$17.6850-Day Range$14.54▼$17.5252-Week Range$12.20▼$20.20Volume493,988 shsAverage Volume211,452 shsMarket Capitalization$6.05 billionP/E RatioN/ADividend YieldN/APrice Target$21.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Bausch + Lomb MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside27.2% Upside$22.00 Price TargetShort InterestBearish15.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.87Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth-4.76%From $1.05 to $1.00 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.47 out of 5 starsMedical Sector938th out of 1,028 stocksOphthalmic Goods Industry6th out of 7 stocks 3.3 Analyst's Opinion Consensus RatingBausch + Lomb has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.00, Bausch + Lomb has a forecasted upside of 27.2% from its current price of $17.29.Amount of Analyst CoverageBausch + Lomb has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.65% of the float of Bausch + Lomb has been sold short.Short Interest Ratio / Days to CoverBausch + Lomb has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Bausch + Lomb has recently increased by 57.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBausch + Lomb does not currently pay a dividend.Dividend GrowthBausch + Lomb does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLCO. Previous Next 3.3 News and Social Media Coverage News SentimentBausch + Lomb has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Bausch + Lomb this week, compared to 2 articles on an average week.Search Interest3 people have searched for BLCO on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bausch + Lomb insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 12.44% of the stock of Bausch + Lomb is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Bausch + Lomb are expected to decrease by -4.76% in the coming year, from $1.05 to $1.00 per share.Price to Earnings Growth RatioBausch + Lomb has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued. Previous Next See Top Rated MarketRank™ Stocks Here About Bausch + Lomb (NYSE:BLCO) StockBausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.Read More Receive BLCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter. Email Address BLCO Stock News HeadlinesFebruary 1, 2023 | wsj.comBausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb's VISUDYNE(R) (Verteporfin for Injection)February 1, 2023 | finance.yahoo.comBausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)February 5, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 24, 2023 | seekingalpha.comBausch + Lomb: Still A Favorable Risk-To-Reward ProspectJanuary 23, 2023 | finance.yahoo.comBausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22January 17, 2023 | finance.yahoo.comBausch + Lomb Acquires AcuFocus, Inc.January 13, 2023 | theglobeandmail.comBausch & Lomb: Top 25 Undervalued Dividend Stocks on TSX (BLCO)January 9, 2023 | finance.yahoo.comBausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare ConferenceFebruary 5, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 9, 2023 | finance.yahoo.comBausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™January 5, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Bausch + Lomb Corporation (BLCO)January 5, 2023 | finance.yahoo.comBausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 4, 2023 | finance.yahoo.comBausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in OphthalmologyJanuary 3, 2023 | finance.yahoo.comBausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness MonthDecember 27, 2022 | finance.yahoo.comImplied Volatility Surging for Bausch + Lomb (BLCO) Stock OptionsDecember 22, 2022 | finance.yahoo.comBausch + Lomb Amends CEO Separation AgreementDecember 21, 2022 | benzinga.com7 Analysts Have This to Say About Bausch & LombDecember 13, 2022 | finance.yahoo.comBausch + Lomb Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating DropsDecember 12, 2022 | finance.yahoo.comBausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Win Gold for Most Environmentally Friendly Service of the Year from Best in Biz AwardsNovember 29, 2022 | finance.yahoo.comBausch + Lomb's Biotrue® Hydration Plus Multi-Purpose Solution Receives Product of the Year Award from Business Intelligence Group's 2022 BIG Awards for BusinessNovember 23, 2022 | markets.businessinsider.comWhat 7 Analyst Ratings Have To Say About Bausch & LombNovember 15, 2022 | finance.yahoo.comBausch + Lomb Reports More Than 58 Million Units of Contact Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling ProgramsNovember 9, 2022 | seekingalpha.comBausch + Lomb: A Solid Play In Challenging Economic TimesNovember 7, 2022 | finance.yahoo.comBausch + Lomb Announces Participation at the 5th Annual Evercore ISI HealthCONx ConferenceNovember 6, 2022 | seekingalpha.comBausch + Lomb Corporation (BLCO) Q3 2022 Earnings Call TranscriptNovember 4, 2022 | cnbc.com4 of our stocks are in the news. Here's the Club's take on each developmentNovember 2, 2022 | markets.businessinsider.comBausch + Lomb Announces Third-Quarter 2022 ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter. Email Address BLCO Company Calendar Today2/05/2023Next Earnings (Confirmed)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Ophthalmic goods Sub-IndustryN/A SectorMedical Current SymbolNYSE:BLCO CUSIPN/A CIK1860742 Webwww.bausch.com Phone905-695-7700FaxN/AEmployees12,500Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.00 High Stock Price Forecast$35.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+21.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio16.47 P/E Growth1.77Net Income$182 million Net Margins1.54% Pretax Margin4.27% Return on Equity4.59% Return on Assets3.21% Debt Debt-to-Equity Ratio0.36 Current Ratio1.55 Quick Ratio1.05 Sales & Book Value Annual Sales$3.77 billion Price / Sales1.61 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares350,000,000Free FloatN/AMarket Cap$6.05 billion OptionableNot Optionable BetaN/A Key ExecutivesMr. Joseph C. Papa (Age 67)CEO & Director Comp: $4.08MMr. Osama A. Eldessouky (Age 51)Exec. VP & CFO Comp: $1.37MMs. Christina M. Ackermann (Age 58)Exec. VP, Gen. Counsel & Pres of Ophthalmic Pharmaceuticals Comp: $1.63MMr. Joseph F. Gordon (Age 58)Pres of Global Consumer, Surgical & Vision Care Comp: $1.36MMs. Kelly WebberExec. VP & Chief HR OfficerDr. Yehia Hashad M.D. (Age 56)Exec. VP of R&D and Chief Medical officer Mr. Louis W. Yu (Age 73)Exec. VP & Chief Quality Officer Mr. Dennis AsharinExec. VP and Chief Global Manufacturing & Supply Chain OfficerMore ExecutivesKey CompetitorsSTAAR SurgicalNASDAQ:STAANational VisionNASDAQ:EYEWarby ParkerNYSE:WRBYCooper CompaniesNYSE:COOApellis PharmaceuticalsNASDAQ:APLSView All CompetitorsInsiders & InstitutionsHodges Capital Management Inc.Bought 317,632 shares on 2/3/2023Ownership: 0.135%Illinois Municipal Retirement FundBought 32,184 shares on 2/3/2023Ownership: 0.009%Simplex Trading LLCSold 61,200 shares on 2/2/2023Ownership: 0.000%River Road Asset Management LLCBought 87,776 shares on 2/1/2023Ownership: 0.472%Wolverine Asset Management LLCBought 62,965 shares on 2/1/2023Ownership: 0.018%View All Institutional Transactions BLCO Stock - Frequently Asked Questions Should I buy or sell Bausch + Lomb stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last twelve months. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLCO shares. View BLCO analyst ratings or view top-rated stocks. What is Bausch + Lomb's stock price forecast for 2023? 15 brokerages have issued twelve-month price objectives for Bausch + Lomb's stock. Their BLCO share price forecasts range from $15.00 to $35.00. On average, they anticipate the company's stock price to reach $22.00 in the next year. This suggests a possible upside of 27.2% from the stock's current price. View analysts price targets for BLCO or view top-rated stocks among Wall Street analysts. How have BLCO shares performed in 2023? Bausch + Lomb's stock was trading at $15.51 at the start of the year. Since then, BLCO shares have increased by 11.5% and is now trading at $17.29. View the best growth stocks for 2023 here. Are investors shorting Bausch + Lomb? Bausch + Lomb saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 6,020,000 shares, an increase of 57.2% from the December 31st total of 3,830,000 shares. Based on an average trading volume of 437,600 shares, the days-to-cover ratio is presently 13.8 days. Approximately 15.7% of the shares of the company are sold short. View Bausch + Lomb's Short Interest. When is Bausch + Lomb's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our BLCO earnings forecast. How can I listen to Bausch + Lomb's earnings call? Bausch + Lomb will be holding an earnings conference call on Wednesday, February 22nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "47443". What guidance has Bausch + Lomb issued on next quarter's earnings? Bausch + Lomb updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.70 billion-$3.75 billion. When did Bausch + Lomb IPO? (BLCO) raised $788 million in an initial public offering (IPO) on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share. What is Bausch + Lomb's stock symbol? Bausch + Lomb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BLCO." Who are Bausch + Lomb's major shareholders? Bausch + Lomb's stock is owned by many different retail and institutional investors. Top institutional shareholders include River Road Asset Management LLC (0.47%), Segantii Capital Management Ltd (0.14%), Hodges Capital Management Inc. (0.14%), Wolverine Asset Management LLC (0.02%), Illinois Municipal Retirement Fund (0.01%) and Renaissance Capital LLC (0.00%). How do I buy shares of Bausch + Lomb? Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bausch + Lomb's stock price today? One share of BLCO stock can currently be purchased for approximately $17.29. How much money does Bausch + Lomb make? Bausch + Lomb (NYSE:BLCO) has a market capitalization of $6.05 billion and generates $3.77 billion in revenue each year. How many employees does Bausch + Lomb have? The company employs 12,500 workers across the globe. How can I contact Bausch + Lomb? The official website for the company is www.bausch.com. The company can be reached via phone at 905-695-7700. This page (NYSE:BLCO) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.